- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05283525
Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21) (VNI)
Efficacy Of Trimrox On Body Composition, Body Weight, And Anthropometric Parameters In 100 Healthy Male And Female Volunteers
Protocol Number: VNI/121/TrimRox:
A unique stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical formulation, TrimROXTM, has been developed in a cGMP and NSF-certified manufacturing facility that is CFR-111 A compliant as well as having a BRC A rating, ensuring compliance with the Global Food Safety Initiative (GFSI). The investigators developed a stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical technology that effectively addresses directly and indirectly all the contributing factors. The investigators will conduct a 90-day study investigation in 100 study participants to assess the efficacy of TRCAP21 on diverse anthropometric aspects including chest, upper arms, waist/belly, hips and thighs, body weight, height, body mass index (BMI), and overall health and well-being.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
- Doplněk stravy: Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches
- Doplněk stravy: Oxygen Saturation
- Doplněk stravy: Total Blood Chemistry
- Doplněk stravy: Adverse Event Monitoring
- Doplněk stravy: Body Weight Monitoring
- Doplněk stravy: Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health
Detailní popis
CDC reports that in the USA, the prevalence of obesity was 40% in adults between 20 and 39 years, 44.8% in adults between 40 and 59 years, and 42.8% in people 60 years and older. Furthermore, the CDC emphasized that 49.6% of non-Hispanic Black adults exhibited the highest age-adjusted prevalence of obesity, which is followed by the occurrence of 44.8% in Hispanic adults, 42.2% in non-Hispanic White adults, and 17.4% in non-Hispanic Asian adults. Obesity-related conditions include diverse cardiovascular diseases and dysfunctions, stroke, Type 2 Diabetes, and certain types of cancer that are some of the leading causes of preventable, premature death. The estimated annual medical cost of obesity in the United States was $147 billion in 2008 US dollars; the medical cost for people who have obesity was $1,429 higher than those of normal weight. Overall, the obesity epidemic is increasing at an alarming rate worldwide. Because of the alarming rise in the global obesity epidemic, the terminologies "weight loss" and "weight management" have become common descriptors, even in the medical and scientific communities. However, the correct scientific terminology should more accurately refer to express changes in body composition and size, especially in regard to a reduction in fat mass, rather than weight reduction alone. In fact, the investigators will demonstrate that focusing on "weight" as an appropriate measuring criterion constitutes a contradiction and a misconception to the natural sequence of metabolic events in the body recomposition process. Overall, the term 'weight loss' is an unreliable metric as it automatically places the primary focus on the heaviness of the body and does not provide a correct and accurate perspective for evaluating healthy changes in metabolism, body composition, or size. For example, losing a small amount of fat while increasing muscle density, strength, and performance could result in a small increase in weight, as muscle is heavier than fat. It is especially important to highlight that fat is the lightest of pertinent macro molecules in the human body, lighter than water, muscle mass, and bone. Moreover, fat is usually 'the last to go' in the body recomposition process, therefore, creating short-term expectations in weight loss is erroneous and maybe even fraudulent.
A more comprehensive and accurate approach therefore is to fundamentally restore healthy efficient aerobic metabolism, improving oxygen utilization and management that enables competent cellular waste removal. Adversarial factors to that objective involve nutrient deprivation (the most common factor employed by weight loss products and programs), the imposition of various types of stimulants inducing, via feedback, regulatory energy-conserving retaliation in the form of even greater survival insurance storage; triggering the "yo-yo" rebound weight regain. Moreover, conventional weight loss tactics seem to ignore the biological, genetic, and metabolic consequences that occur with aging. Diminishing hormonal potencies are crucially important considerations that need to be addressed in the obesity epidemic. Cellular oxygen deprivation-induced anaerobic pathologies exacerbate and amplify the effects of diminished hormone functionality and contribute to an increasingly sluggish metabolism with increased fat, glycogen, and water storage. This also increases the detrimental strain on the cardiovascular system, kidneys, GI tract, and microbiome to name a few. The objective is to restore optimal systemic aerobic metabolism using a novel TRCAP21 nutraceutical formulation that addresses multiple biological pathways in order to reduce survival panic, restore survival safety, and correct metabolic homeostasis.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: DR DEBASIS BAGCHI, PhD
- Telefonní číslo: 19259486951
- E-mail: debasisbagchi@gmail.com
Studijní místa
-
-
Pennsylvania
-
Huntingdon Valley, Pennsylvania, Spojené státy, 19006
- Nábor
- Dr Bruce S. Morrison
-
Kontakt:
- Bruce S Morrison, DO
- Telefonní číslo: 215-947-9131
- E-mail: drmorrisonfm@gmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria
- Agrees to sign written and audio-visual informed consent.
- Fully understand the risks and benefits of the study
- Male and Female Subjects (age: 30-70 Y)
- Subjects are deemed to be acceptable for this study by their physician
Exclusion Criteria
- Subjects who are unwilling or uncooperative subjects
- Subjects were excluded who had impaired hepatic functions i,e., SGOT/SGPT >2.5 X
- Subjects suffering from type 1 diabetes
- Subjects suffering from type 2 diabetes or anyone else that has a blood glucose levels >180 mg/dl or HbA1c > 8.
- Subjects who were suffering from coronary artery disease or high blood pressure >180/100
- Subjects who were exhibiting abnormal hepatic or kidney functions (ALT or AST > 2 X greater than normal value); elevated creatinine, males > 125 μmol/L or 1.4mg/dl
- Subjects who have cancer and are suffering from a malignancy.
- Hypersensitivity to the investigational supplement
- Subjects who had used any known weight management supplement for the last 2 months.
- History of blood coagulation and bleeding (coagulopathies)
- Incidence of high alcohol intake (more than 2 standard drinks/day).
- Psychiatric disorder/disability provide signed informed consent.
Existing medical condition of the participant, which may be detrimental to the study and subject's overall well-being.
__________________________________________________________________
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Komparátor placeba: Placebo Group #1 (6.75 gms Once-A-Day)
Placebo Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 placebo sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
Ostatní jména:
|
Komparátor placeba: Placebo Group #2 (6.75 gms Twice-A-Day)
Placebo Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 placebo sachets; To be taken one in the morning in an empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
Ostatní jména:
|
Aktivní komparátor: TRCAP21 Group #1 (6.75 gms Once-A-Day)
TRCAP21 Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 TRCAP21 sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
Ostatní jména:
|
Aktivní komparátor: TRCAP21 Group #2 (6.75 gms Twice-A-Day)
TRCAP21 Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 TRCAP21 sachets; To be taken one in the morning in empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Ostatní jména:
0 - 90 Days of Treatment
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Anthropometric Measurement of the Chest (in Inches)
Časové okno: 0 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
Časové okno: 30 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
30 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
Časové okno: 60 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
60 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
Časové okno: 90 Days of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Časové okno: 0 Day of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Časové okno: 30 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Časové okno: 60 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Časové okno: 90 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Časové okno: 0 Day of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Časové okno: 30 Days of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Časové okno: 60 Days of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Časové okno: 90 Days of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Časové okno: 0 Day of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Časové okno: 30 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Časové okno: 60 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Časové okno: 90 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Časové okno: 0 Day of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Časové okno: 30 Days of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Časové okno: 60 Days of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Časové okno: 90 Days of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
90 Days of Treatment
|
Body Weight Measurement (in Kilograms)
Časové okno: 0 Day of Treatment
|
Body Weight Measurements (in Kilograms)
|
0 Day of Treatment
|
Body Weight Measurement (in Kilograms)
Časové okno: 30 Days of Treatment
|
Body Weight Measurements (in Kilograms)
|
30 Days of Treatment
|
Body Weight Measurement (in Kilograms)
Časové okno: 60 Days of Treatment
|
Body Weight Measurements (in Kilograms)
|
60 Days of Treatment
|
Body Weight Measurement (in Kilograms)
Časové okno: 90 Days of Treatment
|
Body Weight Measurements (in Kilograms)
|
90 Days of Treatment
|
Height Measurement (in Centimeters)
Časové okno: 0 Day of Treatment
|
Height Measurement (in Centimeters)
|
0 Day of Treatment
|
Height Measurement (in Centimeters)
Časové okno: 30 Days of Treatment
|
Height Measurement (in Centimeters)
|
30 Days of Treatment
|
Height Measurement (in Centimeters)
Časové okno: 60 Days of Treatment
|
Height Measurement (in Centimeters)
|
60 Days of Treatment
|
Height Measurement (in Centimeters)
Časové okno: 90 Days of Treatment
|
Height Measurement (in Centimeters)
|
90 Days of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Časové okno: 0 Day of Treatment
|
BMI (body mass index)(kg/m^2)
|
0 Day of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Časové okno: 30 Days of Treatment
|
BMI (body mass index)(kg/m^2)
|
30 Days of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Časové okno: 60 Days of Treatment
|
BMI (body mass index)(kg/m^2)
|
60 Days of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Časové okno: 90 Days of Treatment
|
BMI (body mass index)(kg/m^2)
|
90 Days of Treatment
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Časové okno: 0 Day of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
0 Day of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Časové okno: 30 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
30 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Časové okno: 60 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
60 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Časové okno: 90 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
90 Days of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Časové okno: 0 Day of Treatment
|
Pulse Rate (beats per minute; bpm)
|
0 Day of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Časové okno: 30 Days of Treatment
|
Pulse Rate (beats per minute; bpm)
|
30 Days of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Časové okno: 60 Days of Treatment
|
Pulse Rate (beats per minute; bpm)
|
60 Days of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Časové okno: 90 Days of Treatment
|
Pulse Rate (beats per minute; bpm)
|
90 Days of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Časové okno: 0 Day of Treatment
|
Pulse Ox Measurement (SpO2%)
|
0 Day of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Časové okno: 30 Days of Treatment
|
Pulse Ox Measurement (SpO2%)
|
30 Days of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Časové okno: 60 Days of Treatment
|
Pulse Ox Measurement (SpO2%)
|
60 Days of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Časové okno: 90 Days of Treatment
|
Pulse Ox Measurement (SpO2%)
|
90 Days of Treatment
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- VNI-TRIMROX-2022
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Časový rámec sdílení IPD
Kritéria přístupu pro sdílení IPD
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- ANALYTIC_CODE
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Změny tělesné hmotnosti
-
M.D. Anderson Cancer CenterNáborImunitní kontrolní bod terapieSpojené státy
-
Hillel Yaffe Medical CenterNeznámý
-
National Research Centre, EgyptDokončenoBílá skvrnitá léze zubuEgypt
-
Hospital St. Joseph, Marseille, FranceDokončeno
-
Escola Superior de Tecnologia da Saúde do PortoDokončenoLatentní myofasciální spouštěcí bod horního trapézového svaluPortugalsko
-
Al-Azhar UniversityZápis na pozvánku
-
Texas A&M UniversityDokončenoLéze bílé skvrnySpojené státy
-
3MUniversity of Tennessee Health Science CenterDokončeno
-
University Hospital, MontpellierDokončeno